Cancer Associated E17K Mutation Causes Rapid Conformational Drift in AKT1 Pleckstrin Homology (PH) Domain

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Kumar, Ambuj ^a   Purohit, Rituraj ^a,b  

^a VIT UNIVERSITY   (India)

^b Human Genetics Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLECKSTRIN; PROTEIN AKT1; PROTEIN INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; GENE MUTATION; METHODOLOGY; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NEOPLASM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; SIMULATION;

BENZIMIDAZOLES; DATABASES, PROTEIN; HUMANS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MUTATION; PROTEIN STABILITY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; THERMODYNAMICS;

MURINAE;

EID: 84878535001     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064364     Document Type: Article

References (41)

1. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer, Nature. 448: 439-44.
2. Lindhurst MJ, Sapp JC, Teer JK, Johnston JJ, Finn EM, et al. (2011) A mosaic activating mutation in AKT1 associated with the Proteus syndrome. N Engl J Med 365: 611-9.
3. Landgraf KE, Pilling C, Falke JJ, (2008) Molecular mechanism of an oncogenic mutation that alters membrane targeting: Glu17Lys modifies the PIP lipid specificity of the AKT1 PH domain. Biochemistry 47: 12260-9.
4. Shoji K, (2009) The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145-8.
5. Kim MS, Jeong EG, Yoo NJ, Lee SH, (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. Br J Cancer 98: 1533-5.
6. Vogiatzi P, Giordano A, (2007) Following the tracks of AKT1 gene, Cancer Biol Ther. 6: 1521-4.
7. Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, et al. (2010) AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 116: 88-91.
8. Mahmoud IS, Sughayer MA, Mohammad HA, Awidi AS, EL-Khateeb MS, et al. (2008) The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias. Br J Cancer 99: 488-90.
9. Zenz T, Döhner K, Denzel T, Döhner H, Stilgenbauer S, et al. (2008) Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations. Br J Haematol 141: 742-3.
10. Staal SP, (1987) Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci U S A 84: 5034-5037.
11. Knobbe CB, Reifenberger G, (2003) Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-39-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13: 507-518.
12. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, et al. (2001) AKT1/PKBa kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159: 431-437.
13. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Rev Cancer 2: 489-501.
14. Pilling C, Landgraf KE, Falke JJ, (2011) The GRP1 PH domain, like the AKT1 PH domain, possesses a sentry glutamate residue essential for specific targeting to plasma membrane PI(3,4,5)P(3). Biochemistry 50: 9845-56.
15. Jo H, Lo PK, Li Y, Loison F, Green S, et al. (2011) Deactivation of Akt by a small molecule inhibitor targeting pleckstrin homology domain and facilitating Akt ubiquitination. Proc Natl Acad Sci U S A 108: 6486-91.
16. Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, et al. (1993) The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential. Oncogene 8: 1957-1963.
17. Cantley LC, Neel BG, (1999) New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245.
18. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, et al. (2004) PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer 112: 407-410.
19. Zilberman DE, Cohen Y, Amariglio N, Fridman E, Ramon J, et al. (2009) AKT1 E17K pleckstrin homology domain mutation in urothelial carcinoma. Cancer Genet Cytogenet 191: 34-7.
20. Mohamedali A, Lea NC, Feakins RM, Raj K, Mufti GJ, et al. (2008) AKT1 (E17K) mutation in pancreatic cancer. Technol Cancer Res Treat 7: 407-8.
21. Guo G, Qiu X, Wang S, Chen Y, Rothman PB, et al. (2010) Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells. Oncogene 29: 3845-53.
22. Rajendran V, Purohit R, Sethumadhavan R, (2011) In silico investigation of molecular mechanism of laminopathy cause by a point mutation (R482W) in lamin A/C protein. Amino Acids 43: 603-615.
23. Kumar A, Purohit R, (2012) Computational investigation of pathogenic nsSNPs in CEP63 protein. Gene 503: 75-82.
24. Kumar A, Purohit R, (2012) Computational screening and molecular dynamics simulation of disease associated nsSNPs in CENP-E. Mutat. Res. 738-739: 28-37.
25. Kumar A, Rajendran V, Sethumadhavan R, Purohit R, (2012) In silico prediction of a disease-associated STIL mutant and its affect on the recruitment of centromere protein J (CENPJ). FEBS Open Bio 2: 285-293.
26. Kumar A, Rajendran V, Sethumadhavan R, Purohit R (2013) Computational Investigation of Cancer-Associated Molecular Mechanism in Aurora A (S155R) Mutation. Cell Biochem Biophys. (DOI 10.1007/s12013-013-9524-9.
27. Kumar A, Rajendran V, Sethumadhavan R, Purohit R (2013) Relationship between a point mutation S97C in CK1δ protein and its affect on ATP binding affinity. J Biomol Struct Dyn. (DOI:10.1080/07391102.2013.770373.
28. Rajendran V, Sethumadhavan R (2013) Drug resistance mechanism of PncA in Mycobacterium tuberculosis. J Biomol Struct Dyn. DOI: 10.1080/07391102.2012.759885.
29. Balu K, Purohit R, (2013) Mutational analysis of TYR gene and its structural consequences in OCA1A, Gene. 513: 184-95.
30. Berman HM, Battistuz T, Bhat TN, Bluhm WF, Bourne PE, et al. (2002) The Protein Data Bank, Acta. Crystallogr. D. Biol. Crystallogr 58: 899-907.
31. Hess B, Kutzner C, van der Spoel D, Lindahl E, (2008) GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4: 435-447.
32. Gallivan JP, Dougherty DA, (1999) Cation-pi interactions in structural biology, Proc Natl Acad Sci USA. 96: 9459-64.
33. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, et al. (2006) CASTp: computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues, Nucleic Acids Res. 34: W116-8.
34. Mashiach E, Schneidman-Duhovny D, Peri A, Shavit Y, Nussinov R, et al. (2010) An integrated suite of fast docking algorithms. Proteins 78: 3197-204.
35. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791.
36. Berendsen HJC, Postma JPM, van Gunsteren WF, Dinola A, Haak JR, (1984) Molecular dynamics with coupling to an external bath. J Chem Phys 8: 3684-3690.
37. Cheatham TE III, Miller JL, Fox T, Darden TA, Kollman PA, (1995) Molecular dynamics simulations on solvated biomolecular systems: the particle mesh Ewald method leads to stable trajectories of DNA, RNA, and proteins. J Am Chem Soc 14: 4193-4194.
38. Purohit R, Rajendran V, Sethumadhavan R, (2011) Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants. J Biomol Struct Dyn 29: 137-152.
39. Purohit R, Rajendran V, Sethumadhavan R, (2011) Relationship between mutation of serine residue at 315th position in M. tuberculosis catalase-peroxidase enzyme and isoniazid susceptibility: an in silico analysis. J Mol Model 17: 869-877.
40. Balu K, Rajendran V, Sethumadhavan R, Purohit R (2013) Investigation of Binding Phenomenon of NSP3 and p130Cas Mutants and Their Effect on Cell Signalling. Cell Biochem Biophys. DOI: 10.1007/s12013-013-9551-6.
41. Psachoulia E, Sansom MS, (2008) Interactions of the pleckstrin homology domain with phosphatidylinositol phosphate and membranes: characterization via molecular dynamics simulations, Biochemistry. 47: 4211-20.